China’s generics push a bitter pill for pharma to swallow
Innovator drug companies express concern over the large number of generics being approved before patents expire in China
A troubling trend of “ruleless competitors” is worrying pharmaceutical companies, according to heads of IP at multinational businesses in China.
In 2019 alone, the National Medical Products Administration (NMPA) has approved 10 generics in the course of 10...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.